And Royalty Pharma has paid a king’s ransom.
The move shines a light on Ichnos, though none of the groups with clinical-stage Ox40 blockers has yet reported full phase 2 data.
After revealing plans to buy one of its holdings out of a Spac, Roivant itself moves towards a blank-cheque company listing.
The company overhauls senior management as its lead technology continues being passed from pillar to post. What is going on?
And consolidation in the diagnostics space is only just beginning.
Cancer diagnosis is likely to see a huge resurgence in demand as the pandemic ebbs, and Invitae wants to be ready.
The quest for the Grail is beset with challenges.
A radionuclide deal between Lantheus and Noria mirrors that done by Novartis and Sofie, among others.
The Japanese group pays $120m for Anima’s preclinical small-molecule approach.